When Nothing Feels Good Anymore
You know the feeling intellectually. You remember that your daughter’s laugh used to fill you with warmth, that cooking used to be meditative, that finishing a project used to matter. But somewhere along the way the volume knob turned down, and now you go through the motions without the feeling that made the motions worthwhile.
That experience has a clinical name: anhedonia. It comes from the Greek “a” (without) and “hedone” (pleasure). Psychiatrists divide it into two types. Consummatory anhedonia means reduced enjoyment during an activity you’re already doing—the food is in your mouth but it doesn’t taste like anything emotionally. Motivational anhedonia means reduced drive to pursue rewarding activities in the first place—you can’t generate the energy to start.
Anhedonia affects somewhere between 37% and 70% of people with major depression. But here is the part that makes it clinically urgent: anhedonia has its own independent relationship with suicidality, separate from depression severity as a whole. A person can score moderately on a depression questionnaire and still be at elevated risk if anhedonia is their dominant symptom. They are not necessarily sad. They are empty. And emptiness, for many people, is harder to endure than sadness.
Why Standard Antidepressants Often Miss Anhedonia
SSRIs and SNRIs work primarily by increasing the availability of serotonin (and norepinephrine, in the case of SNRIs) in the synaptic cleft. This can be effective for sadness, rumination, and anxiety. But anhedonia is not primarily a serotonin problem.
The reward system runs on dopamine and glutamate. The nucleus accumbens, a small structure deep in the brain that functions as the reward center, relies on glutamatergic inputs from the prefrontal cortex and hippocampus to generate motivated behavior. When those glutamate signals weaken—which chronic stress reliably produces—the reward circuit goes quiet. You lose the ability to anticipate pleasure, to exert effort toward goals, to persist when something gets difficult.
SSRIs do not directly strengthen glutamatergic transmission in reward circuits. In some patients, they actually make anhedonia worse by dampening emotional range altogether—a phenomenon clinicians call emotional blunting. This is not a side effect in the traditional sense. It is the medication working on the serotonin system while leaving the glutamate-driven reward pathways unchanged or suppressed.
This is why so many patients report a specific frustration: “The medication helped with the crying and the worst of the anxiety, but I still don’t feel like myself. I still don’t care about things.” The serotonin system improved. The reward circuitry did not.
What the 2025 Neuron Study Revealed
In May 2025, researchers at Washington University in St. Louis and the National Institute of Mental Health published a study in Neuron that mapped exactly how ketamine reverses anhedonia at the cellular level. The paper is titled “Ketamine rescues anhedonia by cell-type- and input-specific adaptations in the nucleus accumbens,” and it represents one of the most detailed pictures we have of how any antidepressant treatment restores reward function.
The researchers subjected mice to chronic social defeat stress—a well-validated animal model that produces anhedonia (measurable as reduced sucrose preference and decreased effort for rewards). Then they administered a single dose of ketamine and tracked what happened at the synaptic level.
Their key findings:
- Chronic stress weakened excitatory synapses on D1-MSNs in the nucleus accumbens. D1-expressing medium spiny neurons are the “go” cells of the reward system. When glutamatergic synapses onto these neurons weaken, motivational drive declines. The stressed mice showed measurably weaker synaptic strength at exactly these connections.
- A single dose of ketamine restored those weakened synapses. Ketamine strengthened excitatory input from both the medial prefrontal cortex and the ventral hippocampus onto the D1-MSNs. The prefrontal input helps sustain reward-directed effort once started; the hippocampal input helps trigger reward-seeking in the first place.
- This repair happened at specific inputs to specific cell types. Ketamine did not globally increase excitation throughout the brain. It selectively strengthened the exact connections that chronic stress had weakened. This specificity helps explain why ketamine can reverse anhedonia without producing mania or indiscriminate impulsivity.
- The behavioral recovery tracked the synaptic repair. As the synapses strengthened, the mice returned to seeking rewards, exerting effort, engaging with tasks, and persisting in the face of difficulty. The timeline of synaptic change matched the timeline of behavioral recovery.
Ketamine rescues stress-induced decreased strength of excitatory synapses on NAc D1-MSNs at medial prefrontal cortex and ventral hippocampal inputs, restoring approach behavior, exertion of effort, task engagement, and persistence. — Neuron, May 2025
This study matters because it moves the conversation past “ketamine is an antidepressant” to something more specific: ketamine repairs the reward circuitry that anhedonia damages. It does not simply elevate mood. It rebuilds the capacity for motivated behavior at the level of individual synapses on identified cell types.
Clinical Evidence for Ketamine and Anhedonia
The 2025 Neuron study provides the mechanism. The clinical literature provides the outcomes in humans.
A systematic review and meta-analysis published in the Journal of Affective Disorders examined ketamine’s anti-anhedonic effects across multiple studies in treatment-resistant unipolar and bipolar depression. The conclusion: ketamine exhibited a significant anti-anhedonic effect across all analyses conducted. The effect was measurable within hours of infusion, which is consistent with the rapid synaptic changes observed in the preclinical research.
A Frontiers in Psychiatry study (2024) tracked anhedonia severity across a series of seven ketamine infusions. Responders showed significant improvement by the 7th infusion with continued gains at follow-up. Notably, even patients classified as non-responders on overall depression measures reported significant reductions in anhedonia by the 5th infusion. Anhedonia improved even when other depression symptoms were slower to respond.
A translational study using the Probabilistic Reward Task (a validated measure of reward learning in humans) found that ketamine improved anhedonic phenotypes across species—in both the animal models and the human participants. This cross-species consistency is notable because it means the reward-circuit repair observed in the preclinical research is likely the same mechanism producing the clinical improvements seen in patients.
Research from the National Institute of Mental Health found that ketamine produced specific anti-anhedonic effects in treatment-resistant bipolar depression, with improvements in reward-related brain activity measurable on functional neuroimaging. The effect was distinct from the general antidepressant response, confirming that ketamine acts on the reward system through a separate pathway from its effects on sadness or anxiety.
How Ketamine Reaches the Reward System
Understanding why ketamine works for anhedonia requires understanding the difference between how ketamine works and how SSRIs work.
SSRIs slow the reuptake of serotonin, allowing more serotonin to remain in the synapse. This affects serotonergic circuits throughout the brain. It takes 4-6 weeks for downstream changes to produce clinical improvement, and those changes do not reliably extend to the glutamate-dependent reward circuitry in the nucleus accumbens.
Ketamine is an NMDA receptor antagonist. When it blocks NMDA receptors, it triggers a rapid cascade:
- Increased AMPA receptor signaling (the fast excitatory receptors)
- Release of BDNF (brain-derived neurotrophic factor)
- Activation of the mTOR pathway, which promotes new synapse formation
- Strengthening of glutamatergic connections in the prefrontal cortex and nucleus accumbens
This cascade produces new synaptic connections within hours. In anhedonia specifically, the connections being restored are the ones between the prefrontal cortex, hippocampus, and nucleus accumbens that chronic stress degraded. The neuroplastic window that ketamine opens is particularly relevant here: it creates a period of enhanced synaptic flexibility during which the reward system can rebuild.
This is not a temporary masking of symptoms. The synaptic changes persist beyond the presence of ketamine in the body, which is why patients experience sustained improvement between infusions.
What Anhedonia Looks Like in Daily Life
Clinical descriptions of anhedonia can sound abstract. In practice, our patients describe it in very concrete terms:
- “I used to love running. Now I can’t make myself put on my shoes.”
- “My kids are right there and I know I love them, but I can’t feel it.”
- “Food has no taste. Music sounds flat. Sex is mechanical.”
- “People ask what I want to do and I genuinely don’t want anything.”
- “I’m not sad. I’m just... absent.”
If these descriptions resonate, you are not failing at being a person. Your reward circuitry is running on weakened connections. That is a neurobiological state, not a character deficiency. And neurobiological states can change.
Who Responds Best
The clinical data suggests some patterns in who responds well to ketamine for anhedonia specifically:
- Patients with treatment-resistant depression where anhedonia is the dominant symptom. If medications have helped your sadness or anxiety but left the emptiness untouched, ketamine targets a system those medications do not reach.
- Patients who have experienced emotional blunting on SSRIs. If your medication flattened your emotional range rather than restoring joy, the problem is likely glutamatergic rather than serotonergic.
- Patients with multiple lifetime depressive episodes. The research suggests that ketamine response for anhedonia correlates with longer illness history, possibly because chronic stress produces more pronounced reward circuit degradation that ketamine is well-positioned to address.
- Patients whose anhedonia affects motivation and effort, not just pleasure. The 2025 Neuron study specifically showed restoration of approach behavior and effortful engagement—the “wanting” dimension, not only the “liking” dimension.
One important caveat from the research: a 2026 study found that anhedonia non-response was associated with fewer lifetime depressive episodes and absence of substance use disorder. This underscores that treatment should be personalized. During your consultation, we discuss your specific symptom profile, treatment history, and whether the pattern of your depression suggests ketamine is likely to help.
What Treatment Looks Like
At Music City Ketamine, IV ketamine infusions for anhedonia follow the same safety and monitoring standards we maintain for all patients. Marla Peterson, CRNA, administers and monitors every session with continuous pulse oximetry, blood pressure, and heart rate tracking.
The standard protocol begins with a series of six infusions over two to three weeks. For anhedonia specifically, many patients report noticing the first shifts in motivation or emotional responsiveness within the first few sessions. The full anti-anhedonic effect typically builds across the series.
What patients often describe is not a dramatic mood swing but a quiet return of interest. The urge to text a friend back. The ability to notice that a sunset is beautiful and have that register as something felt rather than something merely observed. The willingness to start a task without requiring extraordinary willpower to override the flatness.
Our therapy dogs, Walter White and Wilma, are often part of these sessions. Several patients have told us that interacting with the dogs during treatment was the first moment they noticed genuine warmth returning—a small thing, but meaningful when you have been numb for months.
Maintenance infusions are individualized. Some patients sustain improvement for weeks between sessions; others benefit from more regular intervals. We track your response and adjust the schedule based on how long your gains persist.
Working with the Neuroplastic Window
The neuroplastic window following each infusion is particularly important for anhedonia. During this period of enhanced synaptic flexibility, the brain is more capable of forming new reward associations and strengthening positive behavioral patterns.
This means the days following an infusion are an opportunity. Engaging in activities that were previously rewarding—even if they still feel muted—can help consolidate the synaptic changes ketamine initiated. We encourage patients to experiment gently: take a short walk, listen to a song that used to mean something, cook a meal with attention. You are not forcing feelings. You are providing the reward system with opportunities to practice using its newly restored connections.
Integration with a therapist during this period can also help. Behavioral activation—a structured approach to gradually reintroducing pleasurable activities—is well-matched to the neuroplastic window because it provides the experiential data that new synapses need to stabilize.